In the published article, there was an error in the author list. The equal contribution of Saeedeh Ghorbanalipoor, Shirin Emtenani as first authors and that of Enno Schmidt and Ralf J. Ludwig as last authors had not been indicated. The corrected author list appears below.
Saeedeh Ghorbanalipoor1‡, Shirin Emtenani1‡, Melissa Parker2, Mayumi Kamaguchi 1, Colin Osterloh 1, Manuela Pigors 1, Natalie Gross 1, Stanislav Khil’chenko 1, Anika Kasprick 1, Sabrina Patzelt1, Diana Wortmann1, Ibrahim O. Ibrahim1, Kentaro Izumi1, Stephanie Goletz1, Katharina Boch3, Kathrin Kalies4, Katja Bieber1, Paul Smith2†, Enno Schmidt1§ and Ralf J. Ludwig1*§
†Present Address: Paul Smith, Connect Biopharma, San Diego, CA, United States
‡These authors have contributed equally to this work
§These authors have contributed equally to this work
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
animal model, neutrophils, autoimmunity, pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid, signal transduction, phosphatidylinositol 3-kinase (P13k)
Citation
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil’chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E and Ludwig RJ (2022) Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases. Front. Immunol. 13:1099535. doi: 10.3389/fimmu.2022.1099535
Received
15 November 2022
Accepted
16 November 2022
Published
30 November 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Ghorbanalipoor, Emtenani, Parker, Kamaguchi, Osterloh, Pigors, Gross, Khil’chenko, Kasprick, Patzelt, Wortmann, Ibrahim, Izumi, Goletz, Boch, Kalies, Bieber, Smith, Schmidt and Ludwig.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ralf J. Ludwig, ralf.ludwig@uksh.de
‡These authors have contributed equally to this work
§These authors have contributed equally to this work
†Present address: Paul Smith, Connect Biopharma, San Diego, CA, United States
This article was submitted to Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.